Last reviewed · How we verify
tobramycin / Bramitob
At a glance
| Generic name | tobramycin / Bramitob |
|---|---|
| Also known as | Bramitob, Tobrineb, Actitob, Bethkis |
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia (PHASE4)
- Pharmacokinetic Study of Bramitob® Administered for Inhalation by PARI eFlow® vs PARI LC® PLUS Nebulizer (PHASE1)
- A Single Arm 48-Week Follow-on Safety Study to a Core Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® (PHASE3)
- A Study Comparing the Efficacy and Tolerability of Tobrineb®/Actitob®/Bramitob® Versus TOBI® (PHASE3)
- Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |